Search the Community
Showing results for tags 'Clinical trials'.
Found 4 results
-
Presented by Eliza Geer, MD Medical director, Multidisciplinary Pituitary & Skull Base Tumor Center Associate Attending, Endocrine Service Memorial Sloan Kettering Cancer Center After registering you will receive a confirmation email with details about joining the webinar. Contact us at webinar@pituitary.org with any questions or suggestions. Date: Wednesday, July 18, 2018 Time: 10:00 AM - 11:00 AM Pacific Daylight Time 1:00 PM - 2:00 PM Eastern Daylight Time Webinar Description: Learning Objectives: Review Cushing’s disease treatment guideli-
- 1
-
-
- webinar
- cushings disease
- (and 1 more)
-
Clinical trials are research studies that test new treatments to see how well they work. Our Pituitary and Skull Base Tumor Center is leading clinical trials investigating new medical therapies for patients with Cushing’s disease and acromegaly. They are also involved in quality-of-life studies aimed at improving long-term follow-up care for patients who need it. Our experts can help determine which clinical trials are right for you. The following clinical trials for pituitary tumors are currently enrolling new patients. To learn more about a particular study, choose from the list belo
-
Rank Status Study 1 Recruiting Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Condition: Cushing's Syndrome Intervention: Drug: CORT125134 2 Recruiting Cushing's Disease Complications Condition: Cushing's Disease Intervention: Other: Exams and questionnaires 3 Recruiting The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis Condi
-
This study is currently recruiting participants. Verified August 2012 by Novartis First Received on June 14, 2011. Last Updated on August 23, 2012 History of Changes Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) ClinicalTrials.gov Identifier: NCT01374906 Purpose This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
